Abstract
The pharmacokinetics and cell trafficking dynamics of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride (FTY720), a novel immunosuppressive agent, were examined in cynomolgus monkeys (three males and three females). After single doses of 0.1 mg/kg p.o. or i.v. bolus and 1 mg/kg p.o. were administered to the animals, the concentrations of FTY720, and the numbers of lymphocytes, CD20+CD2-B cells, and CD2+CD20-T cells in blood were measured over 23 days. A linear three-compartment model characterized the time course of FTY720 concentrations with a terminal half-life of about 31 h, clearance of about 0.53 l/h/kg, and bioavailability of about 38%. The dynamic responses were not area under the curve (or dose) proportional for either males or females. An indirect response model with a distribution pool captured the cell trafficking data for all doses for each cell type, where initial blood counts (R0) were about 7650, 2100, and 5250 cells/μl; maximum fractional inhibition (Imax) about 0.88, 0.85, and 0.91; influx (kin) about 6014, 1312, and 5662 cells/μl/h; efflux (kout) about 0.798, 0.555, and 1.08 h−1; intercompartmentalkcp about 0.134, 0.192, and 0.082 h−1; and intercompartmental kpcrate constants about 3.9 × 10−4, and 0.016 and 8.9 × 10−6 h−1 for lymphocytes, B cells, and T cells, respectively. The inhibition concentration IC50 was about 0.48 μg/l for all cells, which was remarkably low. The apparent distribution volumes of peripheral pool (Vp) were markedly larger than blood volume (Vb) for all cells. TheImax for cell trafficking was achieved at doses smaller than that producing graft protection, indicating stronger central than peripheral effects of this drug. The profound cell trafficking effects of FTY720 can be readily captured and interpreted with an extended indirect response model.
Footnotes
-
This research was supported by Novartis Pharma AG, Basel, Switzerland, and by Grant GM24211 from the National Institute of General Medical Sciences, National Institutes of Health.
- Abbreviations:
- PK
- pharmacokinetics
- PD
- pharmacodynamics
- k10
- systemic elimination rate constant
- F
- bioavailability
- ka
- first-order absorption rate constant of drug
- Tlag
- lag time of drug being absorbed
- AGI
- drug amount in gastrointestinal tract
- Ai (i = 1–3)
- drug amount in compartment i
- Vi (i = 1–3)
- distribution volume of drug in compartment i
- C1
- drug concentration in compartment 1
- kij (i
- j = 1, 2, 3), transfer rate constant of drug between compartments i and j
- λi (i = 1–3)
- exponential disposition slopes
- kin
- zero order input constant of cells into central compartment
- kout
- first-order output constant of cells
- kcp and kpc
- transfer rate constants of cells between compartments
- R0
- initial blood counts
- R
- lymphocyte concentration in blood
- Rp
- total cell content in peripheral pool
- Vb
- blood volume
- Vp
- apparent distribution volume of cells in peripheral pool
- Imax
- maximal fractional inhibition
- ABEC
- area between baseline and effect curve
- AUC
- area under the curve
- MRT
- mean residence time
- CL
- clearance
- AIC
- Akaike's information criterion
- Y-32919
- 2-amino-2-[2-(4-octyloxyphenyl)ethyl]propane-1,3-diolhydrochloride
- Received September 25, 2001.
- Accepted December 27, 2001.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|